• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

Arterial and Venous Thromboembolism in ALK-Rearrangement-Positive Non-small Cell Lung Cancer: A Population-Based Cohort Study
CONCLUSIONS: In this study, we observed a higher VTE risk, but not ATE risk, in patients with ALK-rearranged NSCLC relative to those without ALK rearrangement. Prospective studies are warranted to evaluate thromboprophylaxis in ALK-positive NSCLC.PMID:37014824 | DOI:10.1093/oncolo/oyad061
Source: The Oncologist - April 4, 2023 Category: Cancer & Oncology Authors: Oded Icht Avi Leader Erez Batat Lilach Yosef Tzippy Shochat Daniel A Goldstein Elizabeth Dudnik Galia Spectre Pia Raanani Ariel Hammerman Alona Zer Source Type: research

Healthcare systems data in the context of clinical trials - A comparison of cardiovascular data from a clinical trial dataset with routinely collected data
CONCLUSION: Concordance between datasets was lower than anticipated and the HSD used could not straightforwardly replace current trial practices, nor directly identify protocol-defined CVS events. Further work is required to improve the quality of HSD and consider event definitions when designing clinical trials incorporating HSD.PMID:36933612 | DOI:10.1016/j.cct.2023.107162
Source: Clinical Lung Cancer - March 18, 2023 Category: Cancer & Oncology Authors: Archie Macnair Matthew Nankivell Macey L Murray Stuart D Rosen Sally Appleyard Matthew R Sydes Sylvia Forcat Andrew Welland Noel W Clarke Stephen Mangar Howard Kynaston Roger Kockelbergh Abdulla Al-Hasso John Deighan John Marshall Mahesh Parmar Ruth E Lan Source Type: research

Neurovascular Manifestations of Iron-Deficient Anemia: Narrative Review and Practical Reflections through a Teaching Case
Conclusions: IDA is a common but treatable condition that, independently or synergically, may increase the risk of thrombotic events. The diagnostic and therapeutic approach has not yet been defined, and each case should be individually addressed in a pragmatic clinical road map.PMID:36294407 | DOI:10.3390/jcm11206088
Source: Clinical Lung Cancer - October 27, 2022 Category: Cancer & Oncology Authors: Marialuisa Zedde Giacomo Portaro Laura Ferri Francesco Cavallieri Manuela Napoli Claudio Moratti Fabrizio Piazza Franco Valzania Rosario Pascarella Source Type: research

The incidence and risk of cardiovascular events associated with immune checkpoint inhibitors in Asian populations
CONCLUSIONS: Among Asians, immune checkpoint inhibitors were associated with an increased risk of major adverse cardiovascular events, particularly ischemic stroke and pulmonary embolism.PMID:36208180 | DOI:10.1093/jjco/hyac150
Source: Clinical Lung Cancer - October 8, 2022 Category: Cancer & Oncology Authors: Cho-Han Chiang Cho-Hung Chiang Kevin Sheng-Kai Ma Yuan Ping Hsia Yu-Wen Lee Han-Ru Wu Cho-Hsien Chiang Chun-Yu Peng James Cheng-Chung Wei Her-Shyong Shiah Cheng-Ming Peng Tomas G Neilan Source Type: research

Incidence and Risk of Various Types of Arterial Thromboembolism in Patients With Cancer
CONCLUSION: In this observational study of an aggregated US patient population, those with newly diagnosed cancer had increased risk of ATE events. This risk was most elevated in a 330-day window around cancer diagnosis and was consistent across different types of ATE and cancer.PMID:33673912 | DOI:10.1016/j.mayocp.2020.05.045
Source: Clinical Colorectal Cancer - March 6, 2021 Category: Cancer & Oncology Authors: Jiasheng Wang Yeseong D Kim Chang H Kim Source Type: research

Contraindicated Use of Bevacizumab and Toxicity in Elderly Patients With Cancer.
CONCLUSION: Our study demonstrates widespread use of bevacizumab among patients who had contraindications. Black patients were less likely to receive the drug, but those who did were more likely to have a contraindication. Efforts to understand toxicity and efficacy in populations excluded from clinical trials are needed. PMID: 24002522 [PubMed - as supplied by publisher]
Source: Clinical Lung Cancer - September 3, 2013 Category: Cancer & Oncology Authors: Hershman DL, Wright JD, Lim E, Buono DL, Tsai WY, Neugut AI Tags: J Clin Oncol Source Type: research